A new study published in the Journal of Internal Medicine (vol. 15, no. 7) shows that samples handed out by pharmaceutical sales representatives may influence doctors to prescribe drugs they wouldn't have otherwise.
A new study published in the Journal of Internal Medicine (vol. 15, no. 7) shows that samples handed out by pharmaceutical sales representatives may influence doctors to prescribe drugs they wouldn't have otherwise.
The cross-sectional survey of 154 general medicine and family physicians was conducted to determine why and under what circumstances physicians dispense drug samples, if drug samples lead doctors to use medications other than those they normally prescribe and what type of physicians use drug samples.
Of a total of 131 respondents out of 154 surveyed, 17% of physicians reported that they would dispense a drug sample to an insured woman with an uncomplicated lower urinary tract infection. Of those, 95% reported that they would dispense a sample that differed from their normal drug of choice. Twenty-seven percent of respondents said they would dispense a drug sample to an uninsured man with hypertension. Of those, 91% said they would sample a drug that differed from their normal drug of choice. And, when presented with an uninsured woman with depression, 82% of respondents reported they would dispense a drug sample; of those, 49% said they would dispense a drug that differed from their drug of choice.
According to the survey, avoiding cost to the patient was the most frequent reason given for dispensing a drug sample. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.